Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» IBD
IBD
Sanofi, Teva say study results show gut disease drug could be ‘best in class’
BioPharma Dive
Tue, 12/17/24 - 11:59 am
Sanofi
Teva Pharmaceutical
IBD
Merck
Roche
duvakitug
A new biotech tackling IBD joins a race against Lilly and Gilead for a promising pill
Pharma Voice
Thu, 07/18/24 - 11:12 am
Ensho Therapeutics
IBD
Gilead Sciences
Eli Lilly
Lilly inks $3.2B Morphic buyout to snag oral rival to Takeda's IBD blockbuster
Fierce Biotech
Mon, 07/8/24 - 11:54 am
Eli Lilly
Morphic
M&A
Takeda
Entyvio
IBD
AbbVie inks immune disorder drug licensing deal with China's FutureGen
Reuters
Thu, 06/13/24 - 11:07 am
AbbVie
FutureGen
China
IBD
Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?
Motley Fool
Sun, 10/29/23 - 08:44 pm
Roche
Eli Lilly
Pfizer
IBD
ulcerative colitis
Crohn's Disease
mirikizumab
Roche pays $7.1B to Roivant for rights to Telavant’s IBD candidate
BioSpace
Mon, 10/23/23 - 10:35 am
Roche
M&A
Televant
Roivant
RVT-3101
IBD
ulcerative colitis
Crohn’s disease
Sanofi pays Teva $500M to join Merck, Roivant in red-hot bowel disease race
Fierce Biotech
Wed, 10/4/23 - 09:48 am
Sanofi
Teva Pharmaceutical
inflammatory bowl disease
IBD
Merck
Roivant
Celltrion presents infliximab data at ECCO Congress
Clinical Trials Arena
Wed, 07/5/23 - 10:26 am
Celltrion
ECCO
infliximab
IBD
AstraZeneca Teams Up With Startup Quell in Type 1 Diabetes, IBD Cell Therapy Pact
MedCity News
Fri, 06/9/23 - 11:52 am
AstraZeneca
Quell Therapeutics
type 1 diabetes
IBD
cell therapy
AstraZeneca drops Skyrizi rival after seeing R&D timeline spiral
Fierce Biotech
Thu, 06/1/23 - 11:41 am
AstraZeneca
IBD
AbbVie
JNJ
brazikumab
Skyrizi
Stelara
Why Did Pfizer Offload This Potential Mega-Blockbuster Drug?
Motley Fool
Mon, 04/24/23 - 10:18 am
Pfizer
Roivant
IBD
RVT-3101
Merck to buy inflammatory disease drugmaker Prometheus for $10.8B
BioPharma Dive
Sun, 04/16/23 - 11:31 pm
Merck
M&A
Prometheus Biosciences
IBD
FDA declines to approve Eli Lilly's bowel disease drug
Yahoo/Reuters
Thu, 04/13/23 - 10:19 pm
Eli Lilly
IBD
FDA
mirikizumab
AbbVie's Skyrizi aces ulcerative colitis study en route to new IBD showdown with J&J, Takeda
Fierce Pharma
Thu, 03/23/23 - 11:39 am
AbbVie
Skyrizi
IBD
ulcerative colitis
clinical trials
Roivant’s Matt Gline on the hub-and-spoke biotech model and lessons learned from Axovant
Biopharma Dive
Mon, 01/23/23 - 09:45 pm
Roivant Sciences
IBD
Pfizer
Matt Gline
hub-and-spoke
Sanofi and CytoReason target IBD in expanded collaboration
Pharma Live
Mon, 01/23/23 - 11:03 am
Sanofi
CytoReason
IBD
R&D
Satisfai, Virgo, and Alimentiv to boost trials using AI-powered technology
Clinical Trials Arena
Thu, 10/6/22 - 10:55 am
Satisfai Health
Virgo Surgical Video Solutions
Alimentiv
clinical trials
artificial intelligence
IBD
Nestlé wagers $41M on Enterome's preclinical food allergy and IBD prospect
Fierce Biotech
Mon, 07/18/22 - 10:00 am
Nestle
Enterome
food allergies
IBD
Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers
BioSpace
Tue, 06/28/22 - 10:40 am
Boehringer Ingelheim
BiomX
biomarkers
microbiome
IBD
Celsius Therapeutics heats up with $83M and an IBD drug on path to the clinic
MedCity News
Thu, 03/24/22 - 08:37 pm
Celsius Therapeutics
IBD
funding
Pages
1
2
3
next ›
last »